Blog

Raffaele Colombo: sBLA for T-DXd has been accepted by FDA HER2-low or HER2-ultralow breast cancer

Raffaele Colombo/LinkedIn

Oct 4, 2024, 17:28

Raffaele Colombo: sBLA for T-DXd has been accepted by FDA HER2-low or HER2-ultralow breast cancer

Raffaele Colombo shared a post on X:

“sBLA for trastuzumab deruxtecan (T-DXd) has been accepted by FDA (and granted Priority Review) for patients with HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining < IHC 1+) breast cancer after at least one endocrine therapy, based on DESTINY-Breast06.”

Source: Raffaele Colombo/X

Raffaele Colombo, a leading figure in the pharmaceutical industry is the Associate Director of Medicinal Chemistry at Zymeworks Inc.. His leadership and scientific acumen drive the discovery and optimization of novel drug candidates and advancing the treatment landscape for various diseases.

Breast Cancer cancer cancer awareness cancer care DESTINY-Breast06 FDA fight against cancer Global fight against cancer HER2 OncoDaily Oncology Raffaele Colombo

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success

One Hand Gives, Another Takes? Trump, Musk, Congress and Childhood Cancer Research Funding

Fabrice André has been elected as the President of the ESMO for the term 2025-2026

Special Coverage